A Promising New Oral Treatment for LGMD2I: An Update on the Development of BBP-418

ML Bio Solutions is advancing the first-ever oral treatment for LGMD2I - BBP-418 (Ribitol). This treatment may enhance, and partially compensate for, diminished muscle function caused by the genetic driver of the disease.
Watch this video to learn more about this treatment, the drug development process and the status of the BBP-418 clinical studies. Our panelists are Douglas Sproule, MD (Chief Medical Officer, ML Bio Solutions) and Nicholas Johnson, MD (Principle Investigator for the BBP-418 Lead-in Study).
DOUGLAS M. SPROULE, Chief Medical Officer, ML Bio Solutions
Douglas Sproule, M.D., M.Sc., is the Chief Medical Officer at ML Bio Solutions.
NICHOLAS JOHNSON, MD, MSCI, FAAN is an associate professor, division chief of neuromuscular, and vice chair of research in the department of neurology at Virginia Commonwealth University with a focus in inherited neuromuscular disorders.
The webinar was hosted by the Speak Foundation on October 9th, 2020. The Speak Foundation advances the work of pharmaceutical companies working on the development of LGMD therapies. Find out more at www.thespeakfoundation.com or at our the www.nationallgmdconference.com.

[@nickmoreno3686]

Amazing!! Can’t wait to see how phase 1 turns out. Will there be an update on how phase 1 goes?

[@Mavexz]

Are there updates on this drug?

[@thespeakfoundationnon-prof1460]

Hello! Yes, there are new updates on this potential treatment. Are you subscribed to the LGMD News Magazine? There will be an update in the next issue directly from the company.